CAS NO: | 1198153-15-9 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Epaminurad (UR-1102) is an orally active, potent and selectiveURAT1(urate transporter 1) inhibitor, with aKiof 0.057 μM. Epaminurad quite modestly inhibitsOAT1andOAT3(organic anion transporter). Epaminurad is a uricosuric agent. Epaminurad can be used for gout and hyperuricemia research[1]. | ||||||||||||||||||||
IC50& Target | Ki: 0.057 ± 0.036 μM (URAT1), 2.4 ± 0.2 μM (OAT3), 7.2 ± 0.8 μM (OAT1)[1]. | ||||||||||||||||||||
体外研究 (In Vitro) | UR-1102 (0-12 μM) inhibits urate and PAH (p-aminohippuric acid) uptake by HEK293 cells transiently expressing URAT1, OAT1, or OAT3[1]. | ||||||||||||||||||||
体内研究 (In Vivo) | Epaminurad (0-30 mg/kg, Orally, once a day for 3 consecutive days) shows uricosuric and urate-lowering effects[1].
|